Pf Media provides digital publishing and event services for the pharmaceutical and medtech sectors, focusing on delivering commercial success for its clients.

Pf Media

Pf Media | 1,745 followers on LinkedIn. Your home for the latest news, insight, events, job opportunities and developments in the pharmaceutical industry.  | We are Pf Media | All Things Pharma
Your home for the latest news, insight, events, job opportunities and developments in the pharmaceutical industry. 
With our resources, you can keep up to date on your terms. Across print, web and socials, we have the information you need to keep your career ahead.

Digital Markedsføring / Medieproduktion / Podcast / Journalist / Skuespiller / Eventmaker / Radioproduktion

Peder Fenger

Head of Marketing | Performance Specialist

Szymon Strzelewicz

Jinchi Bpy

Projektantka Graficzna

Zuzanna Kopankiewicz

NOW LIVE | Our NEW Pf Media site has the latest pharma news, multimedia insight, opinion and virtual events. #PfMedia #AllThingsPharma pf-media.co.uk

Dan Piggott , Managing Director, Exclusive Access at Uniphar, joined over 500 industry experts at the Alliance of Regenerative Medicine’s Meeting on the Med to discuss the fast-growing environment across the cell and gene therapy sector. Discover Dan's reflections on the event, with Pf Media . #CellAndGene #CGTx #UnipharAccess #Uniphar

Uniphar | Access

The impact of EU pharmaceutical reform - Pf Media https://bit.ly/3KQBWMQ

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media https://bit.ly/3RcqP4s

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media https://bit.ly/3Vw2Mjm

Short or long-term, product launch or staff cover, explore the strategic advantages of vacancy management with Head of Recruitment, Danny Dorward . 🔗 Pf Media link in first comment. #WeAreStarPeople #TrustedToDeliver #vacancymanagement #pharma

Star People

Dare to be disruptive – how to model your European go to market strategy for success - Pf Media https://bit.ly/3ytkpat

Novartis' leukaemia treatment to be made available on the NHS - Pf Media https://bit.ly/44qLjvz

NICE recommends new Novartis treatment for brain tumours - Pf Media https://bit.ly/44hxqQu

Promising new treatment strategy for aggressive form of leukaemia - Pf Media https://bit.ly/4463eb5

Metric
Company Name	Pf Media
Symbol
MSH ID	UK:CO:PF-MEDIA
Market	PRIVATE
Sector	Commercial & Professional Services
Industry	Media & Publishing
Country	GB
Stage
Employee Count
Website	pf-media.co.uk
LinkedIn	pharmaceutical-field
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CO

UK:CO:PF-MEDIA

Pf Media

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue